Targeting the virus at entry To breach the immune system, EBV depends on two surface proteins: gp350 and gp42. It uses these ...

A two-antibody cocktail that targets Nipah and Hendra’s receptor-binding and fusion proteins protects animals from lethal ...

In some parts of the US, up to 30 percent of people may carry the antibody behind a red meat allergy spurred by tick bites, ...

Doctors have few options for patients who develop a life-threatening lung condition called acute respiratory distress ...

Bispecific antibodies have emerged as a transformative class of therapies in multiple myeloma and beyond, but the need for ...

The non-profit Drugs for Neglected Diseases initiative (DNDi) has joined forces with pharma group Serum Institute of India ...

A new HIV vaccine developed by La Jolla Institute for Immunology (LJI), Scripps Research scientists and IAVI has the potential to protect humans from developing HIV infection and AIDS. This HIV ...

Pfizer announced that a late-stage trial in lung cancer for a Seagen-derived ADC, sigvotatug vedotin, has failed. Phase I ...

A monoclonal antibody created by the Nanobiotechnology for Diagnostics group (Nb4D) at the Institute of Advanced Chemistry of Catalonia (IQAC), part of the Spanish National Research Council (CSIC), ...

One receptor can protect antibodies from degradation, extend their half-life and become a drug target itself. Explore the ...

Biotechnology investors often focus on clinical milestones, regulatory approvals, and commercial launches. Yet in antibody ...